Application of AEBP1 gene inhibitor in preparation of medicine for treating cancer
By developing an AEBP1 gene inhibitor, the binding of AEBP1 to the downstream molecule CKAP4 is blocked by the compound, which solves the problem of the difficulty in inhibiting AEBP1 gene activity in the existing technology, and achieves tumor growth inhibition and reduction of immune escape, without toxic side effects.
Patent Information
- Application Number
- CN202411085667.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-08
- Publication Date
- 2024-11-15
AI Technical Summary
Existing technologies are insufficient to effectively inhibit the activity of the AEBP1 gene, leading to tumor growth and progression, and conventional drugs may have toxic side effects.
Develop AEBP1 gene inhibitors to selectively inhibit AEBP1 gene expression or activity through compounds or their pharmaceutically acceptable salts. Use small molecule compounds such as chem-5340199 to block the binding of AEBP1 to the downstream molecule CKAP4, and prepare them into dosage forms such as tablets, powders, and capsules.
It significantly inhibits tumor growth, reduces immune escape, improves patient prognosis, and has no obvious toxic side effects in vitro or in vivo.
Smart Images

Figure CN118948842A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of cancer drugs, and in particular relates to the use of an AEBP1 gene inhibitor in the preparation of a drug for treating cancer. Background Art
[0002] AEBP1, aortic carboxypeptidase-like protein, also known as aortic carboxypeptidase-like protein (ACLP), is a carboxypeptidase with secretory properties. It was first discovered in preadipocytes as a transcriptional repressor with carboxypeptidase activity. AEBP1 interacts with the AE-1 element on the gene AP2 of fatty acid binding protein 4 (FABP4) and participates in the differentiation process of adipocytes.
[0003] In addition, AEBP1 is mainly expressed in tumor-associated fibroblasts (CAFs) in the tumor microenvironment. In the field of oncology, AEBP1 has been confirmed to exist as an oncogene in many types of cancers, including but not limited to breast cancer, glioblastoma, bladder cancer, gastric cancer, colorectal cancer, ovarian cancer, melanoma, and childhood acute lymphoblastic leukemia. AEBP1 regulates key events such as cancer cell proliferation and apoptosis by activating signaling pathways such as NF-κB, PI3K / AKT, and Sonic Hedgehog (Shh), thereby promoting tumor development and progression.
[0004] Therefore, as an oncogene, AEBP1 plays an important role in the occurrence and development of tumors. Summary of the invention
[0005] The present invention targets the AEBP1 gene and discovers a substance that can inhibit the AEBP1 gene. The substance can inhibit the expression of the AEBP1 gene or the activity of the AEBP1 gene, thereby achieving the purpose of inhibiting tumor growth, and has no obvious toxic side effects in vivo or on cells.
[0006] In order to achieve the above object, the present invention can adopt the following technical solutions:
[0007] In one aspect, the present invention provides an application of an AEBP1 gene inhibitor in the preparation of a drug for treating cancer; the AEBP1 gene inhibitor is a compound or a pharmaceutically acceptable salt thereof; wherein the structural formula of the compound is as follows: Wherein, R1, R2 and R3 are independently selected from (CH3)(CH2) n , 0≤n≤4, and n is an integer.
[0008] Preferably, the above-mentioned pharmaceutically acceptable salt may be hydrochloride.
[0009] Preferably, the above cancer is a cancer in which the AEBP1 gene is highly expressed in fibroblasts.
[0010] Preferably, the above cancer includes breast cancer, glioblastoma, bladder cancer, gastric cancer, colorectal cancer, ovarian cancer, melanoma or childhood acute lymphoblastic leukemia.
[0011] Preferably, the above application includes: application of the AEBP1 gene inhibitor in the preparation of a drug for inhibiting the growth of tumor cells.
[0012] Preferably, the above application includes one or more combinations of the following applications: (a) application of an AEBP1 gene inhibitor in the preparation of a drug for inhibiting CAFs cell reprogramming; (b) application of an AEBP1 gene inhibitor in the preparation of a drug for reducing immune escape.
[0013] Preferably, the dosage form of the above-mentioned drug includes tablets, powders, capsules, injections, oral liquids, suspensions or gels.
[0014] Another aspect of the present invention provides a use of a compound or a pharmaceutically acceptable salt thereof in the preparation of an AEBP1 gene activity inhibitor, the structural formula of the compound is shown below: Wherein, R1, R2 and R3 are independently selected from (CH3)(CH2) n , 0≤n≤4, and n is an integer.
[0015] Preferably, the above-mentioned pharmaceutically acceptable salt is hydrochloride.
[0016] Preferably, the above-mentioned AEBP1 gene activity inhibitor is a preparation, and the dosage form of the preparation includes tablets, powders, capsules, injections, oral liquids, suspensions or gels.
[0017] The beneficial effects of the present invention include at least:
[0018] (1) In the present invention, by knocking out the AEBP1 gene in mouse fibroblasts, the growth of mouse tumors can be significantly inhibited.
[0019] (2) The compound Chem-5340199 of the present invention can significantly inhibit the growth of mouse tumors without causing obvious toxic side effects at the cellular and in vivo levels. BRIEF DESCRIPTION OF THE DRAWINGS
[0020] Figure 1 The expression of AEBP1 in various cells in TISCH data;
[0021] Figure 2This is a comparison chart of the overall survival (OS) of colon cancer patients with different AEBP1 expression levels in cancer tissue samples;
[0022] Figure 3 This is a photo of the tumor growth after conditional knockout of AEBP1 on CAFs and MC38 subcutaneous tumor formation;
[0023] Figure 4 This is the time-volume curve of tumor growth after conditional knockout of AEBP1 on CAFs after MC38 subcutaneous tumor formation;
[0024] Figure 5 Schematic diagram of the active pocket of AEBP1 protein;
[0025] Figure 6 The molecular docking of AEBP1 and CKAP4;
[0026] Figure 7 It is the chemdiv-0884-0014 small molecule compound action 2D diagram;
[0027] Figure 8 It is the 2D diagram of the small molecule compound action of chemdiv-K227-0528;
[0028] Fig. 9 It is the 2D diagram of the action of the small molecule compound chemdiv-K788-8686;
[0029] Fig.10 It is the 2D diagram of the small molecule compound action of chemdiv-C741-0658;
[0030] Fig.11 It is the 2D diagram of the small molecule compound action of chemdiv-C200-3928;
[0031] Fig.12 2D diagram of the action of small molecule compounds of chembridge-5324433;
[0032] Fig.13 2D diagram of the action of small molecule compounds of chembridge-5458146;
[0033] Fig.14 2D diagram of the action of small molecule compounds of chembridge-5256224;
[0034] Fig.15 2D diagram of the action of small molecule compounds of chembridge-5256320;
[0035] Fig.162D diagram of the action of small molecule compounds of chembridge-5340199;
[0036] Fig.17 The specific binding of AEBP1 to downstream proteins;
[0037] Fig.18 Identification of CKAP4, a downstream molecule of AEBP1;
[0038] Fig.19 This is a diagram showing the competitive binding of different small molecule inhibitors with AEBP1's downstream molecule CKAP4 in CAFs cells;
[0039] Fig. 20 This is a graph showing the effects of different concentrations of chembridge-5340199 small molecules on the triple-negative breast cancer cell line MDA-MB-231;
[0040] Fig.21 This is a diagram showing the effects of different concentrations of chembridge-5340199 small molecules on the colon cancer cell line MC38;
[0041] Fig. 22 This is a picture showing the actual tumor growth after intervention with different concentrations of chembridge-5340199 small molecules;
[0042] Fig.23 This is the time-volume diagram of tumor growth after intervention with different concentrations of chembridge-5340199 small molecules;
[0043] Fig.24 The figure shows the effect of 10mg / kg 5340199 small molecule on the blood routine indexes of mice (WBC, RBC, Neutrophil, HGB). DETAILED DESCRIPTION
[0044] The examples are provided to better illustrate the present invention, but the present invention is not limited to the examples. Therefore, those skilled in the art may make non-essential improvements and adjustments to the implementation scheme according to the above invention content, which still fall within the protection scope of the present invention.
[0045] The terms used herein are only used to describe specific embodiments and are not intended to limit the present disclosure. Unless the context has a significantly different meaning, expressions in the singular include expressions in the plural. As used herein, it should be understood that terms such as "include", "have", "include" are intended to indicate the presence of features, numbers, materials, or combinations. The terms of the present invention are disclosed in the specification, and are not intended to exclude the possibility that one or more other features, numbers, operations, materials, or combinations thereof may exist or may be added. As used herein, " / " may be interpreted as "and" or "or", depending on the circumstances.
[0046] The embodiment of the present invention provides a use of an AEBP1 gene inhibitor in the preparation of a drug for treating cancer; the AEBP1 gene inhibitor is a compound or a pharmaceutically acceptable salt thereof; wherein the structural formula of the compound is as follows: Wherein, R1, R2 and R3 are independently selected from (CH3)(CH2) n , 0≤n≤4, and n is an integer.
[0047] It should be noted that the AEBP1 gene inhibitor includes a substance that can inhibit the activity of the AEBP1 gene or a substance that inhibits the expression of the AEBP1 gene or a substance that blocks the expression of the AEBP1 gene, which can be a polypeptide, a compound, or other single or mixed substances that can meet the above conditions. The present invention can significantly inhibit the growth of mouse tumors by knocking out the AEBP1 gene and inhibiting the activity of the AEBP1 gene, so the AEBP1 gene inhibitor can be used in the preparation of drugs for treating cancer. In addition, the full name of the AEBP1 gene is Adipocyte Enhancer Binding Protein 1, ID: 165; Ensembl: ENSG00000106624.
[0048] It should also be noted that the above AEBP1 gene inhibitor is selected from the compound ( That is, the following compound chem-5340199) or its pharmaceutically acceptable salt; specifically, the compound of the present invention is screened using the chemdiv library and chembridge library compounds, the molecular active site is determined by determining the active pocket of AEBP1, the small molecules finally screened are docked, the results are sorted by docking score, the ones with high scores are selected for synthesis, and the ability of small inhibitors to block the binding of AEBP1 and its downstream molecule CKAP4 is screened through COIP and other experiments, and it is verified through in vivo and in vitro experiments that the compound can inhibit tumor growth and has no obvious toxic side effects in vivo and in cells.
[0049] It should also be noted that the above-mentioned AEBP1 gene inhibitor can also select AEBP1 gene knockout or knockdown reagents; specifically, the purpose of AEBP1 gene knockout or knockdown reagents is to completely or partially knock out the AEBP1 gene, thereby inhibiting the expression of the AEBP1 gene; the knockout or knockdown methods are methods well known in the art, such as using crisper case9 reagents or adenovirus vectors for knockout.
[0050] In some specific examples, the above compound It is preferred that R1, R2 and R3 are CH3 (i.e. (CH3)(CH2) n In the present invention, independently selected means that in one compound, R1, R2 and R3 may be the same, different, or two may be the same and the other may be different; they may be selected according to specific circumstances.
[0051] In some specific examples, the pharmaceutically acceptable salt may be a hydrochloride.
[0052] It should be noted that the pharmaceutically acceptable salts in the present invention are all salt forms known in the art, preferably hydrochloride, which is more stable and has better pharmaceutical effects.
[0053] In some embodiments, the cancer is a cancer in which AEBP1 gene is highly expressed in fibroblasts.
[0054] It should be noted that AEBP1 has been confirmed to exist as an oncogene in various types of cancers, including but not limited to breast cancer, glioblastoma, bladder cancer, gastric cancer, colorectal cancer, ovarian cancer, melanoma and childhood acute lymphoblastic leukemia. In addition, "high expression" in the present invention refers to an expression level that exceeds that of a healthy body.
[0055] In some specific examples, the above applications include: application of AEBP1 gene inhibitors in the preparation of drugs for inhibiting tumor cell growth.
[0056] In some specific examples, the above applications include one or more combinations of the following applications: (a) application of AEBP1 gene inhibitors in the preparation of drugs for inhibiting CAFs cell reprogramming; (b) application of AEBP1 gene inhibitors in the preparation of drugs for reducing immune escape.
[0057] It should be noted that AEBP1 is an important molecular marker that is associated with poor prognosis in patients in various types of tumors. The above-mentioned compounds or salts thereof can effectively inhibit AEBP1 activity, thereby affecting behaviors related to AEBP1 gene activity, such as CAFs cell reprogramming, immune escape or tumor prognosis.
[0058] In some specific examples, the dosage forms of the above-mentioned drugs include tablets, powders, capsules, injections, oral solutions, suspensions or gels.
[0059] It should be noted that the above-mentioned compounds or salts thereof can be prepared into different dosage forms by adding auxiliary materials according to different needs, such as tablets, powders, liquids, suspensions or gels. The auxiliary materials are all known in the art. For example, the preparation of tablets mainly uses diluents (such as starch, dextrin, sucrose or glycosides, etc.), absorbents (calcium sulfate, calcium hydrogen phosphate or light magnesium oxide, etc.), binders (povidone, syrup or hypromellose, etc.), wetting agents (water, etc.) or disintegrants (dry starch, sodium hydroxymethyl starch or cross-linked polyvinylpyrrolidone, etc.); for example, the preparation of liquids mainly uses bulking agents, suspending agents, emulsifiers or colorants, etc.
[0060] The present invention also provides a use of a compound or a pharmaceutically acceptable salt thereof in the preparation of an AEBP1 gene activity inhibitor. The structural formula of the compound is shown below: Wherein, R1, R2 and R3 are independently selected from (CH3)(CH2) n , 0≤n≤4, and n is an integer.
[0061] It should be noted that the above compounds It is preferred that R1, R2 and R3 are CH3 (i.e. (CH3)(CH2) n In the present invention, independently selected means that in one compound, R1, R2 and R3 may be the same, different, or two may be the same and the other may be different; they may be selected according to specific circumstances.
[0062] In some specific examples, the pharmaceutically acceptable salt is hydrochloride.
[0063] In some specific examples, the AEBP1 gene activity inhibitor is a preparation, and the dosage form of the preparation includes tablets, powders, capsules, injections, oral liquids, suspensions or gels.
[0064] It should be noted that the above-mentioned compounds or salts thereof can be prepared into different dosage forms by adding excipients according to different needs, such as tablets, powders, liquids, suspensions or gels. Excipients are all known in the art. For example, the preparation of tablets mainly uses diluents (such as starch, dextrin, sucrose or glycosides, etc.), absorbents (calcium sulfate, calcium hydrogen phosphate or light magnesium oxide, etc.), binders (povidone, syrup or hydroxypropyl methylcellulose, etc.), wetting agents (water, etc.) or disintegrants (dry starch, sodium hydroxymethyl starch or cross-linked polyvinylpyrrolidone, etc.); for example, the preparation of liquids mainly uses expanders, suspending agents, emulsifiers or colorants. In addition, the above-mentioned preparations do not specifically refer to drugs. In addition to drugs, they can also be used in other forms to achieve the purpose of inhibiting the activity of the AEBP1 gene.
[0065] It should also be noted that the above compounds can be combined with other active ingredients to form a composition to prepare a preparation to increase the therapeutic effect.
[0066] In order to better understand the present invention, the content of the present invention is further explained below in conjunction with specific examples, but the content of the present invention is not limited to the following examples.
[0067] 1. Verification of the correlation between AEBP1 and tumors
[0068] (I) AEBP1 is highly expressed in tumor-associated fibroblasts
[0069] The expression of AEBP1 in each cell population was verified by TISCH (Tumor Immune Single-cell Hub2) online website. The results are as follows Figure 1 As shown, in the colon cancer database, AEBP1 was mainly expressed on fibroblasts.
[0070] In addition, the relationship between AEBP1 expression and the prognosis of tumor patients was verified by the Kaplan-Meier online website. Figure 2 As shown, in the colon cancer database, high expression of AEBP1 predicted poor prognosis of patients.
[0071] (II) Knockout of AEBP1 can effectively inhibit tumor growth
[0072] In the following verification, 6-8 week old wild-type (WT) C57BL / 6J mice were purchased from the Experimental Animal Center of Chongqing Medical University; AEBP1 flox / flox Mice were purchased from Saiye Biotechnology Co., Ltd., S100A4 CreERT The mice were obtained from Shanghai Model Organisms Technology Co., Ltd.; the mouse colon cancer cell MC38 was purchased from American Type Culture Collection.
[0073] (1) Mouse colon cancer cells MC38 were cultured in advance, digested and centrifuged, and counted. 15×10 4 / 100μl / mouse;
[0074] (2)AEBP1 flox / flox and S100A4 CreERT Mice were mated and AEBP1 was constructed flox / flox S100A4 CreERT (hereinafter referred to as AEBP1 cKO) mice, which specifically knock out AEBP1 on mouse fibroblasts (specifically, ERT is an estrogen receptor tag, Cre is a gene editing tool, and S100A4 is a protein mainly expressed on fibroblasts; in S100A4 CreERT In the mouse model, CreERT (Cre recombinase and estrogen receptor fusion protein) is expressed in fibroblasts, and its activity can be induced by estrogen analogs (such as tamoxifen); by administering tamoxifen, CreERT can be specifically activated in fibroblasts, thereby driving the knockout of specific genes; in addition, "flox" means that there are "loxP" sites on both sides of the gene, which are specific sites for Cre enzyme recognition and cutting; S100A4 CreERT Mice and AEBP1 flox / flox Mating can obtain mice with AEBP1 gene specifically knocked out in fibroblasts. Subsequent genotyping can confirm that AEBP1 on fibroblasts is specifically knocked out);
[0075] (3) In WT mice (wild-type mice) and AEBP1 flox / flox S100A4 CreERT Mice (AEBP1 cKO mice) were subcutaneously inoculated with cells on the right side of the midline of the lower abdomen, 100 μl / mouse;
[0076] (4) After inoculation, mice were kept in an SPF environment. Starting from the 7th day, the tumor diameters were measured every two days, and the volume was calculated and the growth curve was drawn. Tumor volume (mm 3 ) = 0.5 × major diameter × minor diameter / 2;
[0077] (5) After measuring for 5 time points, the mice were killed, the tumors were removed, photographed, and weighed;
[0078] The tumors of mice in each group are shown in Figure 3 As shown (where the upper row is the WT group and the lower row is the AEBP1 cKO group), the results showed that the tumor volume of the AEBP1 cKO group was significantly smaller than that of the WT group.
[0079] The changes in the volume of the tumors of each group of mice from day 5 to day 13 are shown in Figure 2. Figure 4As shown, the results showed that the growth of MC38 tumors in the AEBP1 cKO group was significantly slower than that in the WT group.
[0080] 2. Screening of small molecules that inhibit AEBP1 gene activity
[0081] (I) Finding small molecule inhibitors through virtual molecular screening
[0082] (1) Selection and preparation of protein structure
[0083] Used in docking analysis The Prep Wiz module in the software package prepares the protein by performing pretreatment operations such as hydrogenation and dehydration.
[0084] (2) Preparation of small molecule database
[0085] Chemdiv small molecule library and Chembrige small molecule library were used in this virtual screening. All compounds were screened for drug-likeness by Lipinski's rule of five and Veber rule modules in DS4.0 to eliminate molecules with poor drug-likeness. The LigPrep module in the software package was used for preparation, the OPLS_2005 force field was used, and the protonation of the molecule was operated using the Epik module at pH 7.4.
[0086] (3) Finding active sites
[0087] use The SiteMap module in the software package can find the active site of the protein. The active site is shown below. The active site is defined as the docking pocket, such as Figure 5 shown.
[0088] (4) Filtration of compounds with PAINS properties
[0089] Pan-assay interference compounds (PAINS) refer to compounds that, in the process of new drug screening, exhibit "activity" that is not based on the specific interaction between the compound molecule and the protein, but is merely a false positive result; PAINS compounds often disguise themselves as drug binding, creating smokescreens in various screening studies. In order to identify whether the screened compounds are PAINS structures, we used the Canvas 1.1 program to filter them.
[0090] (5) ADME property prediction and cluster analysis
[0091] To predict the pharmacokinetic properties of the screened compounds, the The QikProp 3.2 program in the software package calculated the corresponding properties; the program mainly calculated whether the compound violated Lipinski's five rules and Jorgensen's three rules. These two properties can preliminarily evaluate the ADME characteristics of the compound; the screening compound must meet at least four of the Lipinski five rules to have good oral bioavailability; during the process, the molecules obtained through different pharmacophore screening and docking were merged, the same molecules were eliminated, and the remaining small molecules were subjected to structural clustering analysis using FCFP_6 fingerprints.
[0092] (6) Molecular docking
[0093] Select the optimal docking condition Glide force field, and use the AEBP1 protein file as the receptor for docking research; define the active pocket of the AEBP1 protein receptor mentioned above as a After all molecules and receptor proteins were prepared, the Glide algorithm was used for docking at SP docking accuracy, and other parameters remained default; the docking model of Chem-5340199 small molecule compound and AEBP1 is shown in Figure 6 As shown, chem-5341099 forms hydrogen bonds with amino acids Tyr874 and Lys879 on the AEBP1 protein.
[0094] (7) Analysis of docking results
[0095] The small molecules obtained by the final screening were docked through the Chemdiv small molecule library and the Chembrige small molecule library. The results were sorted by the docking score. Five compounds with high scores and strong interactions were selected from each small molecule library for analysis. The compound numbers, scores and interactions are shown in Table 1 below. The 2D diagram is shown in Figures 7 to 16 shown.
[0096] Table 1 Compound numbers, scoring values and action strength
[0097]
[0098] (II) Searching for downstream binding proteins of AEBP1 by MS and IP
[0099] Proteins from CAFs were extracted, immunoprecipitated with anti-AEBP1 antibodies, and further analyzed by mass spectrometry (MS) (this step was completed by Shanghai Yinghua Biopharmaceutical Technology Co., Ltd.). After screening the downstream binding proteins, they were verified by immunoprecipitation (IP) as follows:
[0100] (1) The cells were seeded in a 10 cm cell culture dish. When the cell density was about 90%, the culture medium was discarded. The cells were washed three times with pre-cooled PBS + PMSF (1 ml + 10 ul). 1 ml of PSB + PMSF was added to each dish. The cells were scraped and transferred to a 1.5 ml EP tube. The tubes were centrifuged at 3000 rpm for 1 minute.
[0101] (2) Add 1 ml of IP buffer to the supernatant in an EP tube and lyse the cells on a Ferris wheel rotator at 4°C for 30 min.
[0102] (3) Centrifuge at 16000g, 4°C for 15 min, take 30ul of the supernatant as input, and take 400ul of the remaining supernatant into new 1.5ml EP tubes as IP samples and IgG samples;
[0103] (4) Add 30ul proteinA / G magnetic beads to IP samples and IgG samples respectively, and rotate on a Ferris wheel at 4°C for 30 minutes to remove non-specific proteins;
[0104] (5) 10000 rpm, 30 s, collect the supernatant, add 2 μg AEBP1 antibody to the supernatant of the IP group, and add 2 μl IgG antibody to the IgG sample, and incubate at 4°C on a Ferris wheel rotator overnight;
[0105] (6) Add 30ul of protein A / G magnetic beads and incubate at 4°C for 2 hours on a Ferris wheel rotator;
[0106] (7) Centrifuge at 1000 rpm for 30 s at 4°C, place 5 ml on a magnetic rack, and remove the supernatant;
[0107] (8) Wash three times with 1 ml IP buffer, spin on a 4°C Ferris wheel for 5 min each time, and centrifuge at 4°C, 4000 rpm;
[0108] (9) Add 20ul 5× loading buffer to IP samples and IgG samples, and add 30ul 5× loading buffer to Input samples, boil at 100°C for 5 minutes;
[0109] (10) Load the sample according to the western blot procedure (separate the sample by SDS-PAGE electrophoresis; transfer the separated protein to polyacrylamide (PVDF) or nitrocellulose membrane; block and wash the membrane, label with primary antibody, wash, label with secondary antibody, wash, and detect the signal. For details, please refer to “Wu, Y., et al., FGFR blockade boosts T cell infiltration into triple-negative breast cancer by regulating cancer-associated fibroblasts. Theranostics, 2022. 12(10): p. 4564-4580”.
[0110] The specific binding of AEBP1 to downstream proteins was verified according to the above method. Fig.17 and Fig.18 As shown, AEBP1 tightly binds to the downstream CKAP4.
[0111] (III) Screening of inhibitor chem-5340199
[0112] In the present embodiment, the above ten small molecule compounds (Table 1) (synthesized by Taoshu Biotechnology Co., Ltd.) were tested using the co-immunoprecipitation (COIP) experimental method, and the method for determining the best drug to prevent AEBP1 from binding to the downstream protein CKAP4 was as follows:
[0113] (1) The cells were seeded in a 10 cm cell culture dish. When the cell density was about 90%, the culture medium was discarded. The cells were washed three times with pre-cooled PBS + PMSF (1 ml + 10 ul). 1 ml of PSB + PMSF was added to each dish. The cells were scraped and transferred to a 1.5 ml EP tube. The tubes were centrifuged at 3000 rpm for 1 minute.
[0114] (2) Add 1 ml of IP buffer to each EP tube and lyse the supernatant for 30 min at 4°C on a Ferris wheel rotator;
[0115] (3) Centrifuge at 16000g, 4°C for 15 min, take 30ul of the supernatant as input, and take 400ul of the remaining supernatant into new 1.5ml EP tubes as IP samples and IgG samples;
[0116] (4) Add 30ul proteinA / G magnetic beads to IP samples and IgG samples respectively, and rotate on a Ferris wheel at 4°C for 30 minutes to remove non-specific proteins;
[0117] (5) 10000 rpm, 30 s, collect the supernatant, add 4 μg CKAP4 antibody and small molecule compound or DMSO to the supernatant of IP group, add 2 μl IgG antibody to IgG sample, and incubate at 4°C on a Ferris wheel rotator overnight;
[0118] (6) Add 30ul of protein A / G magnetic beads and incubate at 4°C for 2 hours on a Ferris wheel rotator;
[0119] (7) Centrifuge at 1000 rpm for 30 s at 4°C, place 5 ml on a magnetic rack, and remove the supernatant;
[0120] (8) Wash three times with 1 ml IP buffer, spin on a Ferris wheel at 4°C for 5 min each time, and centrifuge at 4000 rpm at 4°C;
[0121] (9) Add 20u l5× loading buffer to IP samples and IgG samples, and add 30u l5× loading buffer to Input samples, boil at 100°C for 5 minutes;
[0122] (10) Samples were loaded according to the western blot procedure (samples were separated by SDS-PAGE electrophoresis; separated proteins were transferred to polyacrylamide (PVDF) or nitrocellulose membranes; membrane blocking and washing, primary antibody labeling, washing, secondary antibody labeling, washing, signal detection, for details, refer to “Wu, Y., et al., FGFR blockade boosts T cell infiltration into triple-negative breast cancer by regulating cancer-associated fibroblasts. Theranostics, 2022. 12(10): p. 4564-4580”.
[0123] The above method was used to test the 10 compounds shown in Table 1 for inhibiting the binding of AEBP1 to CKAP4 in CAFs. The results are shown in Table 1. Fig.19 As shown, small molecule compound No. 10, namely chembridge 5340199, has the most significant effect in inhibiting the binding of AEBP1 and CKAP4, which is better than other small molecule compounds.
[0124] 3. Verification of the effect of compound 5340199
[0125] (I) Cell viability test
[0126] (1) The cells were seeded in a 96-well plate, 3000 cells / well, 100 μl / well, and 3 replicates were set up in each group, which was set as a blank control group;
[0127] (2) On the second day, different concentration gradients (0, 10 μM, 30 μM and 100 μM) of the small molecule compound chem-5340199 were added and incubated in an incubator at 37°C and 5% CO2 for 24 h; 10 μl of CCK8 reagent was added to each well of the 96-well plate and protected from light and bubbles;
[0128] (3) The 96-well plate was returned to the incubator and incubated for another 2 h. The absorbance at λ = 450 nm was measured by a full-wavelength microplate reader (TECAN);
[0129] (4) Cell survival rate (%) = [(test well - blank well) / (control well - blank well)] × 100%, where: test well: culture medium containing cells and test compound; control well: culture medium containing cells without test compound; blank well: culture medium without cells and test compound.
[0130] (5) Use GraphPad software to create columns.
[0131] According to the above method, the effect of small molecule compound chem-5340199 on the cell activity of MDA-MB-231 cell line and MC38 cell line was tested respectively. The results are as follows Fig. 20 and 21 As shown, the results showed that different concentrations of chem-5340199 acted on MDA-MB-231 cell line and MC38 cell line respectively, and their cell activities did not change significantly.
[0132] (II) Experiments on inhibition of tumor growth and toxic side effects
[0133] (1) MC38 cells were cultured in advance, digested and centrifuged, and counted. 15×10 4 / 100μl / mouse;
[0134] (2) Cells were subcutaneously inoculated on the right side of the midline of the lower abdomen of mice, 100 μl / mouse;
[0135] (3) After the inoculation, mice were kept in an SPF environment and given chem-5340199 by gavage every two days after tumor formation, with the doses set at 3 mg / kg / mouse / time, 10 mg / kg / mouse / time, and 30 mg / kg / mouse / time. In addition, the blank control group (Vehicle, Veh.) was given corn oil by gavage;
[0136] (4) Starting from the 5th day, the tumor length and short diameter were measured every two days, and the volume was calculated and the growth curve was drawn; tumor volume (mm 3 ) = 0.5 × major diameter × minor diameter / 2;
[0137] (5) After measuring for 5 time points, the blood of the mice was taken out to complete the routine blood test (preparation of working reagents: single reagent method directly use; double reagent method use R1 and R2 separately; set the corresponding parameters (primary and secondary wavelengths: 340nm / 405nm) on the fully automatic biochemical microplate reader (Mindray veterinary fully automatic blood cell analyzer model: BC-2800vet);
[0138] (6) The mice were killed, the tumors were removed, photographed, and weighed.
[0139] The tumors of mice in each group are shown in Fig. 22 As shown, the results showed that the MC38 tumor volume in the experimental group was significantly smaller than that in the blank control group.
[0140] The changes in tumor volume of mice in each group from day 5 to day 13 are shown in Figure 2. Fig.23 As shown, the results showed that the growth of MC38 tumors in the chem-5340199 group was significantly slower than that in the blank control group.
[0141] The blood routine indexes (WBC, RBC, Neutrophil, HGB and PLT) of each group of mice were tested as follows: Fig.24 As shown, the results showed that there was no obvious abnormality in the blood routine index of mice after treatment with chem-5340199, that is, the small molecule compound chem-0199 had no obvious toxic side effects on the blood routine index of mice.
[0142] Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the present invention rather than to limit it. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that the technical solution of the present invention can be modified or replaced by equivalents without departing from the purpose and scope of the technical solution of the present invention, which should be covered by the scope of the claims of the present invention.
Claims
1. Use of an AEBP1 gene inhibitor in the preparation of a drug for treating cancer, wherein the AEBP1 gene inhibitor is a compound or a pharmaceutically acceptable salt thereof; wherein: The structural formula of the compound is shown below: Wherein, R1, R2 and R3 are independently selected from (CH3)(CH2) n , 0≤n≤4, and n is an integer, 0≤n≤4, and n is an integer.
2. The use according to claim 1, characterized in that: The pharmaceutically acceptable salt is the hydrochloride.
3. The use according to claim 1 or 2, characterized in that: The cancer is a cancer in which the AEBP1 gene is highly expressed on fibroblasts.
4. The use according to claim 3, characterized in that: Cancers included breast cancer, glioblastoma, bladder cancer, stomach cancer, colorectal cancer, ovarian cancer, melanoma, or childhood acute lymphoblastic leukemia.
5. The use according to claim 1, 2 or 4, characterized in that: Applications include: Application of AEBP1 gene inhibitor in the preparation of medicine for inhibiting tumor cell growth.
6. The use according to claim 1, 2 or 4, characterized in that: The applications include one or more combinations of the following applications: (a) application of an AEBP1 gene inhibitor in the preparation of a drug for inhibiting CAFs cell reprogramming; (b) application of an AEBP1 gene inhibitor in the preparation of a drug for reducing immune escape.
7. The use according to claim 1, 2 or 4, characterized in that: The dosage forms of the drug include tablets, powders, capsules, injections, oral solutions, suspensions or gels.
8. Use of a compound or a pharmaceutically acceptable salt thereof in the preparation of an AEBP1 gene activity inhibitor, wherein the structural formula of the compound is as follows: in, R1, R2 and R3 are independently selected from (CH3)(CH2) n , 0≤n≤4, and n is an integer.
9. The use according to claim 8, characterized in that: The pharmaceutically acceptable salt is the hydrochloride.
10. The use according to claim 8 or 9, characterized in that: The AEBP1 gene activity inhibitor is a preparation, and the dosage form of the preparation includes tablets, powders, capsules, injections, oral liquids, suspensions or gels.
Citation Information
Cited By
Application of compound or salt thereof in preparation of cancer treatment medicine
CN120204228A
Use of compounds or their salts in the preparation of cancer therapeutic drugs
CN120204228B
